COST-EFFECTIVENESS OF SOTAGLIFLOZIN FOR THE TREATMENT OF RECENT WORSENING HEART FAILURE WITH DIABETES

被引：0
|
作者：
Zhang, Z. [1 ]
Kolm, P. [2 ]
Bhatt, D. [3 ]
Dolman, S. [2 ]
Alva, M. [4 ]
Weintraub, W. [4 ]
机构：
[1] Christiana Care Hlth Syst, Wilmington, DE USA
[2] MedStar Hlth Res Inst, Washington, DC USA
[3] Icahn Sch Med Mt Sinai Hlth Syst, New York, NY USA
[4] Georgetown Univ, Washington, DC USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE429
引用
收藏
页码：S138 / S138
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of Sotagliflozin for the treatment of recent worsening heart failure with diabetes
    Weintraub, W.
    Zhang, Z.
    Kolm, P.
    Dolman, S. F.
    Alva, M.
    Bhatt, D. L.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 174 - 175
  • [2] Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure
    Kim, Jaehong
    Wang, Shanshan
    Sikirica, Slaven
    Shafrin, Jason
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024,
  • [3] Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
    Bhatt, Deepak L.
    Szarek, Michael
    Steg, P. Gabriel
    Cannon, Christopher P.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Lewis, Julia B.
    Riddle, Matthew C.
    Voors, Adriaan A.
    Metra, Marco
    Lund, Lars H.
    Komajda, Michel
    Testani, Jeffrey M.
    Wilcox, Christopher S.
    Ponikowski, Piotr
    Lopes, Renato D.
    Verma, Subodh
    Lapuerta, Pablo
    Pitt, Bertram
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02): : 117 - 128
  • [4] Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis
    Zhang, Weichen
    Yu, Meichen
    Cheng, Guohua
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [5] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction With a Recent Worsening Heart Failure Event
    Dixit, Neal
    Truong, Katie
    Ziaeian, Boback
    Fonarow, Gregg C.
    [J]. CIRCULATION, 2023, 148
  • [6] Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure
    Adena, Michael A.
    Hamann, Gary
    Sindone, Andrew P.
    [J]. HEART LUNG AND CIRCULATION, 2019, 28 (03): : 414 - 422
  • [7] THE COST-EFFECTIVENESS OF BETABLLOCKERS IN THE TREATMENT OF CHRONIC HEART FAILURE
    Lezha, Mimoza
    Miraci, Mirela
    Deliana, Artan
    Zera, Eliverta
    Temali, Indrit
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 140 : S59 - S60
  • [8] Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure
    Verma, Subodh
    Bhatt, Deepak L.
    Dhingra, Nitish K.
    Steg, Gabriel
    Szarek, Michael
    Davies, Michael
    Metra, Marco
    Lund, Lars H.
    Pitt, Bertram
    SOLOIST Investigators, S. O. L. O. I. S. T. Investigators
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (15) : 1546 - 1549
  • [9] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN BRAZIL
    Lacey, M.
    Brouillette, M.
    Libanore, A.
    Lenhart, G.
    Tozato, C.
    Lopes, N.
    Russell, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S63 - S63
  • [10] A cost-effectiveness analysis of candesartan in the treatment of chronic heart failure
    Lamotte, M
    Annemans, L
    Schockaert, B
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A3 - A3
12345